ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

RXRX Recursion Pharmaceuticals Inc

9.17
-0.27 (-2.86%)
2024年6月15日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Recursion Pharmaceuticals Inc RXRX NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.27 -2.86% 9.17 13:00:08
始値 安値 高値 終値 前日終値
9.24 9.165 9.41 9.26 9.44
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/6/1506:12EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
2024/6/1505:29EDGAR2Form 144 - Report of proposed sale of securities
2024/6/1406:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/1405:10EDGAR2Form 144 - Report of proposed sale of securities
2024/6/1205:13EDGAR2Form 144 - Report of proposed sale of securities
2024/6/0805:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0722:00EDGAR2Form 8-K - Current report
2024/6/0623:36EDGAR2Form 144 - Report of proposed sale of securities
2024/6/0607:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0607:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0607:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0607:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0601:30EDGAR2Form 144 - Report of proposed sale of securities
2024/6/0407:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0322:00GLOBERecursion to Participate in Upcoming Investor Conferences
2024/5/3107:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/3105:03EDGAR2Form 144 - Report of proposed sale of securities
2024/5/3004:27GLOBEPower of Recursion OS on Display at Genome Scale in Nature..
2024/5/2505:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2024/5/2505:31EDGAR2Form 8-K - Current report
2024/5/2505:30GLOBERecursion Appoints Robert Hershberg M.D., Ph.D, as New Chair..
2024/5/1808:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/1808:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/1808:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/1808:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/1705:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/1505:25EDGAR2Form 144 - Report of proposed sale of securities
2024/5/1318:00GLOBERecursion Announces Completion of NVIDIA-Powered BioHive-2,..
2024/5/1005:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/1005:01GLOBERecursion Provides Business Updates and Reports First..
2024/5/0221:00GLOBERecursion to Report First Quarter 2024 Business Updates and..
2024/5/0121:01GLOBERecursion to Participate in Upcoming Investor Conferences
2024/4/3021:00GLOBEAltitude Lab Secures Small Business Administration Growth..
2024/4/1621:00GLOBERecursion Appoints Najat Khan, PhD, as Chief R&D Officer and..
2024/4/0221:00GLOBERecursion to Participate in Upcoming Investor Conference
2024/3/2621:00GLOBERecursion Publishes Annual Environmental, Social and..
2024/3/1117:00GLOBERecursion Announces Plans to Open New Office in London
2024/3/0909:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0808:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0707:39EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0706:59EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0606:18EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0204:58GLOBERecursion Hosts Second Annual Rare Disease Day Events for..
2024/3/0121:59GLOBERecursion to Participate in Upcoming Investor Conferences
2024/2/2922:25EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2806:05GLOBERecursion Provides Business Updates and Reports Fourth..
2024/2/2409:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2308:13EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2207:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2106:29EDGAR2Form 144 - Report of proposed sale of securities